Atara biotherapeutics to present positive new tab-cel® clinical data during oral session at esmo immuno-oncology annual congress 2023

Thousand oaks, calif.--(business wire)---- $atra #cart--atara biotherapeutics, inc. (nasdaq: atra), a leader in t-cell immunotherapy, leveraging its novel allogeneic epstein-barr virus (ebv) t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced positive new data for tabelecleucel (tab-cel® or ebvallo™) in patients with relapsed or refractory (r/r) or treatment-naÏve epstein-barr virus-positive post-transplant lymphoproliferative disease involving.
ATRA Ratings Summary
ATRA Quant Ranking